PART I Item 1. B usiness. Overview We are a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (e.g., SARSCoV2, SARSCoV, MERSCoV, and other related infections). The Aligos team has a demonstrated track record of success in drug development ...
Q2 FY2026 — expected 2026-08-08
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001193125-26-092614 | EDGAR | 99K words |
| 2025-03-10 | 2024-12-31 | 0000950170-25-035929 | EDGAR | — |
| 2024-03-12 | 2023-12-31 | 0000950170-24-029953 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0000950170-23-007033 | EDGAR | — |
| 2022-03-10 | 2021-12-31 | 0000950170-22-003365 | EDGAR | — |
| 2021-03-23 | 2020-12-31 | 0001564590-21-014872 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-268203 | EDGAR | 71K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-104042 | EDGAR | — |
| 2025-05-06 | 2025-03-31 | 0000950170-25-063983 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122371 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091828 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0000950170-24-054497 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-058256 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-038045 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017890 | EDGAR | — |
| 2022-11-02 | 2022-09-30 | 0000950170-22-021248 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014815 | EDGAR | — |
| 2022-05-04 | 2022-03-31 | 0000950170-22-007407 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-05 | 0001171843-26-001340 | EDGAR | 3K words |
| 2026-02-04 | 0001193125-26-037558 | EDGAR | — |
| 2025-11-06 | 0001171843-25-007075 | EDGAR | — |
| 2025-08-06 | 0001171843-25-005116 | EDGAR | — |
| 2025-06-26 | 0001193125-25-148905 | EDGAR | — |
| 2025-05-06 | 0001171843-25-002781 | EDGAR | — |
| 2025-03-10 | 0001171843-25-001352 | EDGAR | — |
| 2025-02-12 | 0001193125-25-024838 | EDGAR | — |
| 2025-02-03 | 0001193125-25-019256 | EDGAR | — |
| 2024-11-06 | 0001171843-24-006057 | EDGAR | — |
84 total filings indexed. 56 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001799448 |
| Ticker | ALGS |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.aligos.com |
| Listed | 2020-10-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report